• Customer Care
  • (888) 123-4567

PROCESS DEVELOPMENT SCIENTIST

Rise Therapeutics is recruiting a full-time process development scientist with a background in bacterial fermentation to work in our Rockville, Maryland laboratory. This position offers a unique opportunity for entrepreneurial minded scientists to advance skills and experience necessary for a successful career in the biotechnology industry. The process development scientist will support product development strategies to create new and innovative medicines.

 Required Qualifications

  • Degree (MS and/or PhD) in the life sciences or biomedical engineering
  • Background in bacterial fermentation with experience operating small scale (1-10L) bioreactors
  • Familiarity with good manufacturing practices (GMP)
  • Effective communication skills
  • Ability to contribute in a fast-paced, highly dynamic environment
  • Strong sense of responsibility for deadlines and data accuracy
  • Rigor and attention to detail in all aspects of science
  • Comfort with collaboration in a team-based environment

 

Duties and Responsibilities

  • Establishing control loops to monitor/maintain DO, pH, and other parameters for Gram+ bacterial fermentation
  • Lead projects developing, optimizing, advancing, and scaling fermentation processes
  • Set and execute strategic direction for process development and manufacturing

Benefits

  • Support initiatives to develop new treatments for autoimmunity, infection, and cancer
  • Gain experience working in biotech
  • Mentorship from seasoned research entrepreneurs and business executives
  • Expand relationships/connections with leading biotechnology researchers

 

About Rise Therapeutics

Rise Therapeutics is an emerging, privately held biotech company located in Rockville, Maryland, which develops novel synthetic biology-based medicines. As a product focused company, we leverage our proprietary drug delivery platform and GMP manufacturing infrastructure to create targeted immunologically-directed Live Biotherapeutic Products (LBPs). Rise harnesses novel discoveries in microbiome biology as it relates to regulation of immune function to identify new immune regulatory pathways and develop unique, first-in-class immune modulatory drugs for the treatment of autoimmunity, inflammation, infection, and cancer. For more information, please visit our website at www.risetherapeutics.com

 

Please email your CV or resume to: This email address is being protected from spambots. You need JavaScript enabled to view it.

Title document as "last name first inital-PrDScientist-resume.pdf" e.g. "DoeJ-PrDScientist-resume.pdf"

Our News

Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD.  Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.  

Rockville, MD. Rise Therapeutics, a company that develops innovative immune therapies, announced today that it initiated a new program to develop a novel, immunologically enhanced microbiome drug for the treatment of cancer. This product candidate, R-5780, engages key immune pathways regulated by the microbiome to enhance the effectiveness of immune checkpoint inhibitor (ICI) therapy to treat cancer. Coinciding with the timing of this release, Rise has secured funding to support key product development initiatives for the program.

Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, announced today the publication of the co-authored article, “Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire” in the journal Biomedicines.